We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen ESAs Get Labeling Restrictions, New Warning
Amgen ESAs Get Labeling Restrictions, New Warning
August 1, 2008
The FDA is requiring Amgen to modify physician labeling for its erythropoiesis stimulating agents (ESAs) Aranesp, Epogen with a revised boxed warning and a new restricted indication, using language that Amgen opposed.